This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Branham Law, LLP Investigates AMAG Pharmaceuticals On Behalf Of Stockholders

Branham Law, LLP announces that it is investigating AMAG Pharmaceuticals ( NASDAQ: AMAG) and certain of its officers and directors for potential breaches of fiduciary duties in connection with AMAG’s apparent failure to disclose that users of the Company’s primary drug, Feraheme had suffered adverse reactions, including hospitalizations and one possible death.

Investors who purchased AMAG stock before January 1, 2010 and have held AMAG stock since, or anyone with information about this investigation should contact Branham Law, LLP at or call (855) 722-5910.

On February 4, 2013, the United States First Circuit Court of Appeals reversed the district court’s dismissal of these claims and reinstated the action. After these failures to disclose were revealed, AMAG’s stock fell over $7.00 per share. Subsequent disclosures regarding the company’s rebate program resulted in a further drop of $4.02 per share.

Contact Trey Branham, Branham Law, LLP, 1-855-722-5910, 3900 Elm Street, Dallas, Texas 75226 for additional information.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs